Europe Clears Lyrica for Anxiety
Europe Clears Lyrica for Anxiety
The EU’s clearance enables Pfizer to expand the drug’s uses, a process that has taken longer than the company had hoped.
Although Lyrica is approved for several diseases and conditions in the U.S. and in foreign markets, the Food and Drug Administration rejected Pfizer’s application in mid-2004 for treating generalized anxiety disorder.
Pfizer continues to talk with the FDA about Lyrica as a treatment for the condition, a company spokeswoman said.
Lyrica has been approved in the U.S. for treating epileptic seizures and nerve pain related to diabetes and shingles. The drug is sold in more than 60 countries for various pain and seizure treatments.
More: thestreet.com
